Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03033927 · ClinicalTrials.gov registry record

Predicting Effective Therapy in Pancreatic Cancer

A clinical trial of Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
74
Enrollment target
4
Study locations

NCT03033927: Active study of Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.

NCT03033927 is a study of Pancreatic Cancer and Pancreatic Adenocarcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 74 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (81% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03033927, a study of Pancreatic Cancer and Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
74 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.

Primary Outcome

in patients receiving frontline therapy predicted to be effective versus ineffective based on CTC PGx analysis

Interventions

  • DIAGNOSTIC_TEST CTC isolocation and analysis

Study Locations (4)

New York

  • Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Cancer Center Basking Ridge - Basking Ridge

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2017-01-24
Est. Completion 2026-01-24
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT03033927 still lists

NCT03033927 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (81% lower).

The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which CTC isolocation and analysis is the first listed.

NCT03033927 reports a single indexed study location in New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT03033927 about?

NCT03033927 is a clinical study titled "Predicting Effective Therapy in Pancreatic Cancer". The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.

What is the current status of trial NCT03033927?

This trial is currently active not recruiting. The enrollment target is 74 participants. The study started on 2017-01-24. Estimated completion is 2026-01-24.

What conditions does trial NCT03033927 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma.

What interventions are being tested in trial NCT03033927?

The interventions under investigation include: CTC isolocation and analysis (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03033927?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03033927 being conducted?

This trial has 4 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03033927's enrollment target sits among peer trials

74 130th of 278 higher than 149 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03422731 · 74 participants · Early Phase 1

    Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

  • NCT03804853 · 74 participants · NA

    Rehabilitation Following Reverse Total Shoulder Arthroplasty

  • NCT04065776 · 74 participants · NA

    Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

  • NCT04771156 · 74 participants · Phase 4

    Ketorolac in Palatoplasty

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03033927, the US trial registry maintained by the National Library of Medicine. NCT03033927 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.